DK1146889T3 - Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407 - Google Patents

Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407

Info

Publication number
DK1146889T3
DK1146889T3 DK00904979T DK00904979T DK1146889T3 DK 1146889 T3 DK1146889 T3 DK 1146889T3 DK 00904979 T DK00904979 T DK 00904979T DK 00904979 T DK00904979 T DK 00904979T DK 1146889 T3 DK1146889 T3 DK 1146889T3
Authority
DK
Denmark
Prior art keywords
relates
mycobacterium
differentially expressed
identification
present
Prior art date
Application number
DK00904979T
Other languages
English (en)
Inventor
Peter Jungblut
Stefan H E Kaufmann
Ulrich Schaible
Hans Mollenkopf
Baerbel Raupach
Ursula Zimny-Arndt
Stephanie Lamer
Jens Mattow
Original Assignee
Max Planck Gesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft filed Critical Max Planck Gesellschaft
Application granted granted Critical
Publication of DK1146889T3 publication Critical patent/DK1146889T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
DK00904979T 1999-01-29 2000-01-28 Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407 DK1146889T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99101590 1999-01-29
PCT/EP2000/000690 WO2000044392A2 (en) 1999-01-29 2000-01-28 Identification of specific differentially expressed mycobacterial antigens

Publications (1)

Publication Number Publication Date
DK1146889T3 true DK1146889T3 (da) 2007-10-22

Family

ID=8237440

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00904979T DK1146889T3 (da) 1999-01-29 2000-01-28 Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407

Country Status (10)

Country Link
US (1) US7772386B1 (da)
EP (1) EP1146889B1 (da)
JP (1) JP2002534994A (da)
AT (1) ATE366583T1 (da)
AU (1) AU2667600A (da)
CA (1) CA2361246C (da)
DE (1) DE60035485T2 (da)
DK (1) DK1146889T3 (da)
ES (1) ES2288842T3 (da)
WO (1) WO2000044392A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2135947A1 (en) * 2008-06-17 2009-12-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antagonists of bacterial sequences
ITRM20100411A1 (it) * 2010-07-23 2012-01-24 Massimo Amicosante Uso di sequenze amminoacidiche da mycobacterium tuberculosis o dei loro corrispondenti acidi nucleici per la diagnosi e la prevenzione di infezione tubercolare, relativo kit diagnostico e vaccino.
EP3114211A4 (en) * 2014-03-07 2017-11-22 Institute for Systems Biology Point of care assays to detect the status of tuberculosis infection
US11679150B2 (en) 2020-03-03 2023-06-20 The United States Of America, As Represented By The Secretary Of Agriculture Mycoplasma bovis vaccine product
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
KR102405798B1 (ko) * 2020-06-22 2022-06-08 주식회사 미코라파 Rv2882c-Rv2005c 융합 단백질을 포함하는 결핵 면역 치료용 조성물
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
KR102878370B1 (ko) * 2022-06-17 2025-10-31 주식회사 미코라파 면역활성 부위 융합 단백질을 포함하는 결핵 백신 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2624759B2 (ja) * 1988-03-30 1997-06-25 味の素株式会社 Ｂｃｇ菌由来のｍｐｂ６４蛋白及びその製造法
FR2752425B1 (fr) 1996-08-19 1998-11-13 Pasteur Institut Fragments d'acides nucleiques specifiques de mycobacteries membres du complexe m. tuberculosis et leurs applications pour la detection et le diagnostic differentiel des membres du complexe m. tuberculosis

Also Published As

Publication number Publication date
CA2361246A1 (en) 2000-08-03
WO2000044392A3 (en) 2000-12-07
DE60035485T2 (de) 2008-03-20
EP1146889B1 (en) 2007-07-11
DE60035485D1 (de) 2007-08-23
WO2000044392A2 (en) 2000-08-03
ES2288842T3 (es) 2008-02-01
ATE366583T1 (de) 2007-08-15
CA2361246C (en) 2013-04-16
US7772386B1 (en) 2010-08-10
JP2002534994A (ja) 2002-10-22
AU2667600A (en) 2000-08-18
EP1146889A2 (en) 2001-10-24

Similar Documents

Publication Publication Date Title
Brandt et al. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population
JP4283872B2 (ja) 微生物蛋白質と、この蛋白質を産生する微生物と、該蛋白質のワクチンおよび結核検出での利用
AP1027A (en) Protein K resistant surface protein of neisseria meningitidis.
AU2005214061B2 (en) Polypeptides for inducing a protective immune response against Staphylococcus aureus
DE60139690D1 (de) Immunisierung gegen chlamydia pneumoniae
Okay et al. Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A: 3 in mice
Reglinski et al. Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG
BRPI0208301A8 (pt) vacinas de ácido nucléico para prevenção de infecção por flavivírus
DE60228758D1 (de) Immunisierung gegen chlamydia tracheomatis
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
FI895050A0 (fi) Diagnostiska preparat och vaccin foer mykobakterier i folkhaelso-, medicinsk och veterinaermedicinsk praxis.
Huang et al. Immunization with cell‐free‐generated vaccine protects from Porphyromonas gingivalis‐induced alveolar bone loss
DE60144201D1 (de) Lawsonia intracellularis Impfstoff
Whitlock et al. Protective response to subunit vaccination against intranasal Burkholderia mallei and B. pseudomallei challenge
JP2017513860A (ja) 新規結核菌（ｍ．ｔｕｂｅｒｃｕｌｏｓｉｓ）ワクチン
Cho et al. Extracellular vesicle-associated antigens as a new vaccine platform against scrub typhus
CN101451145A (zh) 基于t细胞表位的结核基因疫苗及其制备方法和应用
AU2667600A (en) Identification of specific differentially expressed antigens
Chelliah et al. Potential DNA vaccine for haemorrhagic septiceamia disease
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
KR20130125771A (ko) 다가 키메라 ospc 백시노겐 및 진단 항원
ATE450545T1 (de) Impfstoff mit lawsonia intracellularis- untereinheit
ES2372187B1 (es) Procedimiento de identificación de animales vacunados frente a brucella.
Tafuku et al. Japanese encephalitis virus structural and nonstructural proteins expressed in Escherichia coli induce protective immunity in mice
Kumari et al. Protective immunity of recombinant LipL21 and I-LipL21 against Leptospira interrogans serovar Autumnalis N2 infection